We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Genome-Wide Expression Analysis Helps Understand Leukemia Development

By LabMedica International staff writers
Posted on 19 Feb 2009
A genome-wide expression analysis compared highly enriched normal blood stem cells and leukemic stem cells, and identified several new pathways that have a key role in cancer development.

Using modern microarray technology, scientists revealed a string of stem-cell pathways; some were already well known and others not previously implicated in leukemia and other cancers. More...
The scientists identified Three thousand and five differentially expressed genes. Among them, a ribosome and T-cell receptor signaling pathway emerged as having a role in regulation of the cancer stem cells.

The direct comparison of leukemic stems cells (obtained by consent from patients) to normal blood stem cells, provided critical insight into the differences found in malignancy that could be used to develop targeted therapy, said Michael W. Becker, M.D., an assistant professor at the James P. Wilmot Cancer Center at the University of Rochester Medical Center (URMC; Rochester, NY, USA). Professor Becker led the genome-wide expression study, which was described in the February 9, 2009 issue of the Proceedings of the [U.S.] National Academy of Sciences (PNAS).

Scientists believe the best way to eradicate cancer could be to find therapies that target cancer's stem cells--the cells thought to be responsible for maintaining the disease. Most cancer treatments today fail to attack cancer at its root, which is why the disease can recur despite aggressive therapy.

Related Links:

University of Rochester Medical Center




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.